Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GRI Bio, Inc.GRI · Entity 8336 | Chief Scientific Officer | September 18, 2025 | September 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GRI Bio, Inc.
Report date September 18, 2025 · Filed September 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2035-09-18 | Direct | 43,222 |
Reported balance
After 2025-09-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-18 · Grant · Acquired 43,222 · Balance 43,222 F1: Options to purchase 29,923 shares vested in full upon the date of grant and options to purchase 13,299 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 29,923 shares vested in full upon the date of grant and options to purchase 13,299 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2025 Filed Sep 22, 2025 20:05 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 43,222 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001971423-25-000003 · wk-form4_1758571544.xml · derivative · entry 1 Chaturvedi Vipin · CIK 0001971423 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,222 Underlying: Common Stock · 43,222 shares Expires 2035-09-18 F1 · derivative.exercise_date: Options to purchase 29,923 shares vested in full upon the date of grant and options to purchase 13,299 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant. Read SEC document |
| August 26, 2025 Filed Aug 27, 2025 12:24 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 11,854 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001824293-25-000140 · wk-form4_1756297493.xml · derivative · entry 1 Chaturvedi Vipin · CIK 0001971423 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,854 Underlying: Common Stock · 11,854 shares Expires 2035-08-26 F1 · derivative.exercise_date: Options to purchase 7,424 shares vested in full upon the date of grant and options to purchase 4,430 shares will vest in 12 substantially equal quarterly installments such that the stock option is fully vested on the third anniversary of the date of grant. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 22:58 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantStock Option (Right to Buy) · Derivative | 43,319 | $0.69 Strike: $0.69 | $29,703.84 |
DisclosureSEC source: 0001824293-25-000034 · wk-form4_1737759490.xml · derivative · entry 1 Chaturvedi Vipin · CIK 0001971423 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,319 Underlying: Common Stock · 43,319 shares Expires 2035-01-23 Read SEC document |
| April 21, 2023 Filed Apr 24, 2023 22:29 UTC | GRI Bio, Inc. GRI · Entity 8336 | GrantCommon Stock | 172,189 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001824293-23-000102 · wf-form4_168237536636728.xml · nonDerivative · entry 1 Chaturvedi Vipin · CIK 0001971423 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,189 F1 · shares: Received in exchange for 4,600,000 shares of common stock of GRI Bio, Inc. ("GRI"), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the "Company"), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the "Merger"). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the "Reverse Split"). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split. F1 · price: Received in exchange for 4,600,000 shares of common stock of GRI Bio, Inc. ("GRI"), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the "Company"), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the "Merger"). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the "Reverse Split"). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.